Einloggen

Thematische Bibliographien / Oxaliplatin / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Oxaliplatin.

Zeitschriftenartikel zum Thema „Oxaliplatin“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 9. Juni 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Oxaliplatin" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Ye, Tong, Chen Wu, Jintong Na, Xiyu Liu, and Yong Huang. "Multi-Pathway Study for Oxaliplatin Resistance Reduction." Current Issues in Molecular Biology 47, no. 3 (March 4, 2025): 172. https://doi.org/10.3390/cimb47030172.

Der volle Inhalt der Quelle

Annotation:

Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications have very limited clinical application. As a first-line medication in antitumor therapy, oxaliplatin must be administered to minimize side effects while achieving anticancer objectives. A new CDC7 inhibitor called XL413 has demonstrated promising antitumor therapeutic effects in a variety of malignant tumors and may have anticancer properties. This offers a fresh viewpoint on how to lessen oxaliplatin resistance and, specifically, increase the potency of already prescribed anticancer therapies. In this paper, the current developments in anticancer therapy are discussed, along with the many mechanisms of oxaliplatin’s antitumor effects, clinical treatment challenges, and related approaches. We conducted more research on oxaliplatin resistance that arose during chemotherapy and searched for ways to lessen it in order to enhance its chemotherapeutic performance. Ultimately, we studied how distinct resistance routes relate to one another. Meanwhile, XL413, a novel CDC7 inhibitor, offers a perspective on the possibilities for developing treatment approaches for this innovation point. The search terms “Oxaliplatin, XL413, drug resistance, cancer treatment,” etc., were applied in the X-MOL and PubMed databases for this review’s literature search. Boolean logic was then employed to maximize the search approach. These databases can offer thorough research data and cover a broad range of biological publications. Excluded publications were works of low relevance, duplicates, or those with insufficient information. The mechanism of oxaliplatin’s anticancer effect, oxaliplatin resistance and its amelioration, and the role of XL413 in oxaliplatin treatment were the main topics of the 140 publications that were ultimately included for analysis.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Ain, Noor ul, Nusrat Bano, Anwar Ejaz Beg, Kamran Hameed, Talha Bin Fayyaz, and Rafia Sadaf. "HEMATOLOGICAL TOXICITY IN RATS;." Professional Medical Journal 24, no. 02 (February 14, 2017): 342–46. http://dx.doi.org/10.29309/tpmj/2017.24.02.525.

Der volle Inhalt der Quelle

Annotation:

Objectives: Oxaliplatin causes hematological toxicities in clinical setting whichlimits its efficacy. The aim of this study is to investigate the therapeutic effects of Andrographispaniculata against hematological toxicity caused by oxaliplatin. Study design: Experimentalanimal study. Period: Study takes 8 month from March 2015 to Oct 2015. Setting: Dow universityanimal house. Method: Wistar albino male rats, divided into 3 equals groups (n=6): GroupN* was a control group (0.9% normal saline), Group NP0 was Oxaliplatin treated group andGroup NP1 was prophylactically treated with Andrographis paniculata followed by Oxaliplatinin order to assess the protective effects of Andrographis paniculata against the hematologictoxicity caused by Oxaliplatin. Results: Prophylactic treatment with Andrographis paniculata(NP1) significantly increases the levels of platelets and neutrophile count compared with thestandard (NP0) (p<0.01) and increases the RBCs count and levels of hemoglobin comparedwith the standard (NP0). Conclusion: Prophylactic treatment with Andrographis paniculata(NP1) was effective in reducing risk of thrombocytopenia, anemia and neutropenia associatedwith Oxaliplatin.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Grothey, A., D. A. Nikcevich, J. A. Sloan, J. W. Kugler, P. T. Silberstein, T. Dentchev, D. B. Wender, H. E. Windschilt, X. Zhao, and C. L. Loprinzi. "Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4025. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4025.

Der volle Inhalt der Quelle

Annotation:

4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. NCI-CTC, an oxaliplatin-specific sNT scale and patient-reported outcome (PRO) questionnaires were used to differentially assess the effect of CaMg on acute (effect on sNT on days 1–4 after oxaliplatin) and chronic sNT (area between curves over whole course of therapy). Results: A total of 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) were available for analysis. Apart from a strong reduction in muscle cramps with CaMg (p=0.002), no difference was found between CaMg and PL in PRO with regard to items reflecting acute sNT (e.g. sensitivity to cold, swallowing of cold liquids, throat discomfort) on days 1–4 after oxaliplatin of any treatment cycle. In contrast, CaMg was able to significantly reduce cumulative sNT in form of numbness in fingers (p=0.02), impaired ability to button shirts (p=0.05), tingling in fingers (p=0.06), and muscle cramps over the course of therapy (p=0.01). Conclusions: In our phase III, placebo-controlled trial, CaMg was able to significantly reduce chronic, cumulative sNT related to oxaliplatin as evaluated by specific PRO questionnaires. No effect was noted on phenomena associated with acute sNT. CaMg can be recommended as neuroprotectant against oxaliplatin-related chronic sNT, oxaliplatin's dose-limiting toxicity. [Table: see text]

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Pires, Lívia Márcia Vidal, and Patrícia Dos Santos Claro Fuly. "Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática." Revista Recien - Revista Científica de Enfermagem 11, no. 35 (September 23, 2021): 382–97. http://dx.doi.org/10.24276/rrecien2021.11.35.382-397.

Der volle Inhalt der Quelle

Annotation:

O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema JBI. Na análise das publicações foram mapeados 15 fatores preditivos, com maior destaque para a dose cumulativa de Oxaliplatina utilizada. O reconhecimento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica, independente da precocidade que possa ser feito, são importantes para a elaboração de estratégias mensuráveis no exercício do cuidado colaborativo e multidimensional.Descritores: Toxicidade, Quimioterapia Combinada, Enfermagem Baseada em Evidências, Cuidados de Enfermagem, Neoplasias Colorretais. Mapping of clinical factors predictive of oxaliplatin-induced peripheral sensory neuropathy: systematic reviewAbstract: The aim of this study was to map the predictive clinical factors of Oxaliplatin-induced Peripheral Sensory Neuropathy. For that, a systematic review was carried out, based on the recommendations of the PRISMA guideline. The PICO strategy was also used to formulate the research question and guide the search in the databases: PubMed, Embase, Scopus, BVS/IBECS and CINAHL. 26 publications were selected for final analysis and inclusion in the review. The publications were classified according to the level of evidence and degree of recommendation, according to the JBI system. In the analysis of the publications, 15 predictive factors were mapped, with greater emphasis on the cumulative dose of Oxaliplatin used. The recognition of clinical predictive factors for Peripheral Sensory Neuropathy, regardless of the precocity that can be done, are important for the development of measurable strategies in the exercise of collaborative and multidimensional care.Descriptors: Toxicity, Combined Chemotherapy, Evidence-Based Nursing, Nursing Care, Colorectal Neoplasms. Mapeo de factores clínicos predictivos de neuropatía sensorial periférica inducida por oxaliplatino: revisión sistemáticaResumen: El objetivo de este estudio fue mapear los factores clínicos predictivos de la Neuropatía Sensorial periférica inducida por oxaliplatino. Para ello se realizó una revisión sistemática, con base en las recomendaciones de la guía PRISMA. También se utilizó la estrategia PICO para formular la pregunta de investigación y orientar la búsqueda en las bases de datos: PubMed, Embase, Scopus, BVS/IBECS y CINAHL. Se seleccionaron 26 publicaciones para su análisis final e inclusión en la revisión. Las publicaciones se clasificaron según el nivel de evidencia y grado de recomendación, según el sistema JBI. En el análisis de las publicaciones se mapearon 15 factores predictivos, con mayor énfasis en la dosis acumulada de Oxaliplatino utilizada. El reconocimiento de factores clínicos predictivos de la Neuropatía Sensorial Periférica, independientemente de la precocidad que se pueda realizar, es importante para el desarrollo de estrategias medibles en el ejercicio de la atención colaborativa y multidimensional.Descriptores: Toxicidad, Quimioterapia Combinada, Enfermería Basada en Evidencias, Cuidado de Enfermera, Neoplasias Colorrectales.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Cho, Soohee, Kristen Miller, Jacqueline Rowley, Ashley Sabus, Shelby Winzent-Oonk, Stacy Bray, Jane Koo, and Jean Mulcahy Levy. "OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i147. http://dx.doi.org/10.1093/neuonc/noac079.542.

Der volle Inhalt der Quelle

Annotation:

Abstract BACKGROUND: Intensive chemotherapy with tandem autologous stem cell transplants (autoSCT) is shown to improve survival for children with CNS malignancy. Platinum-based chemotherapeutic agents in these regimens, mainly cisplatin and carboplatin, have resulted in significant sensorineural hearing loss. Oxaliplatin, a newer platinum-based agent, is considered less ototoxic. Empiric substitution of oxaliplatin for carboplatin in preparative regimens for autoSCT have been tried. However, the survival and ototoxicity outcomes have not been studied. OBJECTIVE: To compare the overall survival and ototoxicity of oxaliplatin versus carboplatin preparatory chemotherapy regimens in children who received tandem autoSCT for treatment of CNS malignancy. METHODS: We performed a retrospective chart review of all pediatric patients with primary CNS tumors who received tandem autoSCT from 2011 to 2018 at Children’s Hospital Colorado. Demographics, clinical outcomes, and medication administration records were extracted from electronic medical records. Hearing evaluations, performed at pre-transplant, after each transplant episode, and at follow-up visits, were reviewed and graded by an audiologist. Comparisons were performed using Fisher’s exact tests and log rank test statistics. RESULTS: 32 pediatric patients with CNS tumors met inclusion criteria. Seven patients received oxaliplatin in place of carboplatin in one or more preparatory regimens. There was no statistically significant difference in overall survival between the two groups (p=0.99). A total of 85 follow-up audiograms were available for assessment, including long-term follow up. Of the 13 audiograms that showed hearing loss, one (8%) had prior oxaliplatin exposure, compared to 18/72 (25%) audiograms without hearing loss had prior oxaliplatin exposure (p=0.28). CONCLUSIONS: Oxaliplatin is effective and well-tolerated when used in lieu of carboplatin in preparatory regimen for autoSCT for pediatric CNS malignancy. This study is limited by its small size. A larger, multi-center study is warranted to confirm oxaliplatin’s safety and effect on survival and ototoxicity in pediatric autoHSCT.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Connors, Jeremy S., Linda Zhang, Koji Sasaki, Courtney D. DiNardo, Nicholas J. Short, Naval Daver, Gautam Borthakur, et al. "Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms." Blood 142, Supplement 1 (November 28, 2023): 4220. http://dx.doi.org/10.1182/blood-2023-190672.

Der volle Inhalt der Quelle

Annotation:

Introduction As a DNA-damaging agent, platinum-based chemotherapy serves as a cornerstone in cancer treatment. However, its widespread use has been associated with increased incidence of therapy-related myeloid neoplasms (t-MNs). Among the three most commonly used platinum chemotherapies - cisplatin, carboplatin, and oxaliplain - oxaliplatin presents a distinctive clinical usage and toxicity profile. Predominantly utilized in treating gastrointestinal tract (GI) cancers, oxaliplatin manifests a distinct toxicity pattern when compared to its counterparts. This variance is supported by a previous study that postulated oxaliplatin-induced cytotoxicity primarily results from ribosomal stress as opposed to a DNA-damage response (Bruno et al. Nature Medicine 2017). Further, epidemiological and anecdotal data suggest a lower incidence of t-MNs associated with oxaliplatin. In this study, we aimed to investigate and compare the clinical manifestations, molecular phenotypes, and patient outcomes associated with t-MNs following exposure to various platinum-based therapies. Methods All patients clinically diagnosed with t-MNs between 2008 and 2022, based upon a presentation with a myeloid neoplasm (AML or MDS) with any previous cancer associated with exposure to platinum-based chemotherapy, at a single center were analyzed. Descriptive statistics were used to compare the clinical and molecular profiles between the groups of patients receiving different types of platinum. Results 153 patients were found to have been diagnosed with t-MNs during the study time period following platinum exposure. 45 (29.4%) had been exposed to only cisplatin, 72 (47.1%) to carboplatin alone, 9 (5.9%) to oxaliplatin alone, 25 (16.3%) to both cisplatin and carboplatin, and 1 each (0.7%) to carboplatin or cisplatin in combination with oxaliplatin. The most frequent primary cancers included non-Hodgkin lymphoma (19.6%), followed by ovarian (14.4%), breast (11.8%), and lung (7.8%). Median time from platinum exposure to t-MN diagnosis was 2.7, 3.5, and 3.6 years for patients having previously received only cisplatin, carboplatin, or oxaliplatin respectively (P value not significant between oxaliplatin vs. cisplatin or vs. carboplatin). In regard to MDS/AML diagnosis ratio, there was no significant difference between cisplatin-only, carboplatin-only, and oxaliplatin-only t-MNs. Cytogenetics data and gene mutation data were available in 139 patients. Del 5q/-5 and/or Del7q/-7 were numerically rare in oxaliplatin-only t-MNs compared to cis-only (22.2% vs. 43.9%, P = 0.285) or carbo-only t-MNs (22.2% vs. 48.4%, P = 0.171). Also, complex karyotype was only found in 1 patient (11%) in oxaliplatin-only t-MNs, whereas 51% and 58% of cisplatin-only and carboplatin-only t-MNs were found to have complex karyotype. Despite the low frequency of complex karyotype in oxaliplatin-only t-MNs, TP53 mutations were prevalent and found in 56%, 60%, and 60% of cisplatin-only, carboplatin-only, and oxaliplatin-only t-MNs, respectively (no statistical difference among the groups). Median overall survival (OS) was not significantly different among the three groups. Conclusion In the patients with t-MNs post-platinum exposure, oxaliplatin-induced t-MNs represented only 6% of the entire cohort, with a significantly lower incidence of t-MN-associated chromosomal abnormalities (del5q/-5, del7q/-7, and complex karyotype). This discrepancy cannot be solely attributed to the less frequent use of oxaliplatin in comparison to other platinum agents. The findings underscore the protective role of oxaliplatin in the development of t-MNs, warranting further investigation in both clinical practice and biological mechanism.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Lipp and Hartmann. "Platinverbindungen: Metabolismus, Toxizität und supportive Strategien." Praxis 94, no. 6 (February 1, 2005): 187–98. http://dx.doi.org/10.1024/0369-8394.94.6.187.

Der volle Inhalt der Quelle

Annotation:

Mit Oxaliplatin wurde der erste Vertreter der DACH-Platin-Verbindungen in die Klinik eingeführt (DACH: Diaminocyclohexan), der bei guter Verträglichkeit die höchste Aktivität zur Behandlung des fortgeschrittenen kolorektalen Karzinoms aufweist. Aufgrund der hohen, gegenüber Cisplatin besseren in vitro-Aktivität des Oxaliplatins auch gegenüber anderen Tumorentitäten sind die klinischen Studien mit Oxaliplatin in den letzten Jahren erheblich ausgeweitet worden. Der breite Einsatz der genannten Platinverbindungen darf allerdings nicht darüber hinwegtäuschen, dass diese Wirkstoffe über beachtliche Nebenwirkungsprofile verfügen, die sich von Platin- zu Platinverbindung – trotz ihrer relativ engen chemischen Verwandtschaft – erheblich unterscheiden, teilweise mit dem pharmakokinetischen Verhalten der einzelnen Wirkstoffe in Verbindung zu bringen sind und nicht selten den Einsatz geeigneter supportiver Strategien erforderlich machen.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1378 (November 2011): 27. http://dx.doi.org/10.2165/00128415-201113780-00098.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1384 (January 2012): 43. http://dx.doi.org/10.2165/00128415-201213840-00174.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1385 (January 2012): 35. http://dx.doi.org/10.2165/00128415-201213850-00129.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1388 (February 2012): 24. http://dx.doi.org/10.2165/00128415-201213880-00093.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1389 (February 2012): 34. http://dx.doi.org/10.2165/00128415-201213890-00124.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 28–29. http://dx.doi.org/10.2165/00128415-201213900-00109.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 29. http://dx.doi.org/10.2165/00128415-201213900-00112.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1391 (March 2012): 32. http://dx.doi.org/10.2165/00128415-201213910-00119.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 714 (August 1998): 12. http://dx.doi.org/10.2165/00128415-199807140-00042.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1161 (July 2007): 20. http://dx.doi.org/10.2165/00128415-200711610-00064.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1166 (August 2007): 19. http://dx.doi.org/10.2165/00128415-200711660-00058.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1174 (October 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711740-00062.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1180 (December 2007): 32. http://dx.doi.org/10.2165/00128415-200711800-00099.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1187 (February 2008): 21. http://dx.doi.org/10.2165/00128415-200811870-00068.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1188 (February 2008): 18–19. http://dx.doi.org/10.2165/00128415-200811880-00060.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1189 (February 2008): 27–28. http://dx.doi.org/10.2165/00128415-200811890-00086.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1191 (March 2008): 20. http://dx.doi.org/10.2165/00128415-200811910-00063.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1192 (March 2008): 27. http://dx.doi.org/10.2165/00128415-200811920-00072.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1194-1195 (March 2008): 28. http://dx.doi.org/10.2165/00128415-200811940-00102.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1123 (October 2006): 15. http://dx.doi.org/10.2165/00128415-200611230-00045.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1128 (November 2006): 15. http://dx.doi.org/10.2165/00128415-200611280-00048.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1129 (November 2006): 16. http://dx.doi.org/10.2165/00128415-200611290-00055.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1138 (February 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711380-00063.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1140 (February 2007): 17. http://dx.doi.org/10.2165/00128415-200711400-00058.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1141 (March 2007): 17–18. http://dx.doi.org/10.2165/00128415-200711410-00061.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1149 (April 2007): 19–20. http://dx.doi.org/10.2165/00128415-200711490-00058.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1156 (June 2007): 20. http://dx.doi.org/10.2165/00128415-200711560-00062.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1160 (July 2007): 24–25. http://dx.doi.org/10.2165/00128415-200711600-00068.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1360 (July 2011): 29. http://dx.doi.org/10.2165/00128415-201113600-00099.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1361 (July 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113610-00111.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1363 (August 2011): 31. http://dx.doi.org/10.2165/00128415-201113630-00122.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1366 (August 2011): 24. http://dx.doi.org/10.2165/00128415-201113660-00090.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113680-00115.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00117.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00119.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1370 (September 2011): 30. http://dx.doi.org/10.2165/00128415-201113700-00105.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1371 (October 2011): 29. http://dx.doi.org/10.2165/00128415-201113710-00109.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1374 (October 2011): 28. http://dx.doi.org/10.2165/00128415-201113740-00100.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00080.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00082.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

L??vi, Francis, Gerard Metzger, Claire Massari, and Gerard Milano. "Oxaliplatin." Clinical Pharmacokinetics 38, no. 1 (January 2000): 1–21. http://dx.doi.org/10.2165/00003088-200038010-00001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Carlson, Robert. "Oxaliplatin." Inpharma Weekly &NA;, no. 1130 (March 1998): 3–4. http://dx.doi.org/10.2165/00128413-199811300-00003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 772 (October 1999): 10. http://dx.doi.org/10.2165/00128415-199907720-00034.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!